2015
Imaging Studies with A2A Receptor Antagonists
Tavares A, Barret O, Seibyl J, Tamagnan G. Imaging Studies with A2A Receptor Antagonists. Current Topics In Neurotoxicity 2015, 10: 207-232. DOI: 10.1007/978-3-319-20273-0_11.Peer-Reviewed Original ResearchPositron emission tomographyValue of PETA2A receptor antagonistsSingle photon emissionPathophysiological progressionReceptor antagonistClinical studiesDifferential diagnosisParkinson's diseaseIodine-123Imaging studiesEmission tomographyNeuropsychiatric disordersSPECT probeSPECT techniqueSPECT radiotracerPET imagingA2AVivo characteristicsBrainSPECTPhoton emissionVivo propertiesRadiotracerRecent reports
2010
Poster 14: Evaluation of Novel Radiotracers Targeting Non-Dopaminergic Striatal Biomarkers in HD: 18F-FPEB and PET Imaging for Metabotropic Glutamate Receptor Type 5 (mGluR5) Expression in Healthy Subjects and Subjects with Huntington Disease (HD)
Russell D, Jennings D, Tamagnan G, Seibyl J, Koren A, Zubal G, Marek K. Poster 14: Evaluation of Novel Radiotracers Targeting Non-Dopaminergic Striatal Biomarkers in HD: 18F-FPEB and PET Imaging for Metabotropic Glutamate Receptor Type 5 (mGluR5) Expression in Healthy Subjects and Subjects with Huntington Disease (HD). Neurotherapeutics 2010, 7: 142. DOI: 10.1016/j.nurt.2009.09.016.Peer-Reviewed Original ResearchHD subjectsHuntington's diseaseMGluR5 expressionTemporal lobeHuman studiesStandardized uptake value ratioPET imagingEnkephalinergic striatal neuronsLimbic cortical areasMean SUV ratioEarly brain changesEarly HD patientsUptake value ratioGray matter areasPromising PET radiotracerCerebellar reference regionSymptomatic HD subjectsNon-human primatesHD patientsNeuron lossStriatal neuronsIntense uptakeHealthy controlsBrain changesAge 44
2009
P2‐016: Multicenter quantitative amyloid PET imaging in Phase III Alzheimer's therapeutic trials: Strategies for achieving good imaging practices in the support of drug development
Seibyl J, Zubal G, Tamagnan G, Marek K. P2‐016: Multicenter quantitative amyloid PET imaging in Phase III Alzheimer's therapeutic trials: Strategies for achieving good imaging practices in the support of drug development. Alzheimer's & Dementia 2009, 5: p265-p265. DOI: 10.1016/j.jalz.2009.04.325.Peer-Reviewed Original ResearchIC‐P‐127: Multicenter quantitative amyloid PET imaging in phase III alzheimer therapeutic trials: Strategies for achieving good imaging practices in the support of drug development
Seibyl J, Zubal G, Tamagnan G, Marek K. IC‐P‐127: Multicenter quantitative amyloid PET imaging in phase III alzheimer therapeutic trials: Strategies for achieving good imaging practices in the support of drug development. Alzheimer's & Dementia 2009, 5: p52-p52. DOI: 10.1016/j.jalz.2009.05.099.Peer-Reviewed Original Research
1996
Radiosynthesis of [18F] N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with positron emission tomography
Chaly T, Dhawan V, Kazumata K, Antonini A, Margouleff C, Dahl J, Belakhlef A, Margouleff D, Yee A, Wang S, Tamagnan G, Neumeyer J, Eidelberg D. Radiosynthesis of [18F] N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nuclear Medicine And Biology 1996, 23: 999-1004. PMID: 9004288, DOI: 10.1016/s0969-8051(96)00155-2.Peer-Reviewed Original Research